[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rheumatoid-arthritis-associated-interstitial-lung-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rheumatoid-arthritis-associated-interstitial-lung-disease":57},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642746","phase-4-treatment-strategy-for-patients-with-ra-ild-100642746",false,"NCT07643038","Treatment Strategy for Patients With RA-ILD","Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease","Inclusion Criteria:\n\n* Fulfillment of the 2010 ACR\u002FEULAR classification criteria for RA.\n* HRCT findings consistent with interstitial lung disease (ILD), including ground-glass opacities, reticular abnormalities, fibrotic linear opacities, traction bronchiectasis, or other compatible features, with pulmonary infection, cardiogenic pulmonary edema, and alveolar hemorrhage excluded. The extent of ILD involvement must be ≥20% on HRCT, as assessed by central review.\n* Pulmonary function impairment defined as forced vital capacity (FVC) \\\u003C80% of predicted and\u002For diffusing capacity of the lung for carbon monoxide (DLCO) \\\u003C70% of predicted.\n* Participants receiving glucocorticoids prior to enrollment must be on a stable dose of prednisone ≤10 mg\u002Fday (or equivalent) for at least 4 weeks before baseline.\n* Participants receiving a csDMARD prior to enrollment must be on a stable regimen for at least 4 weeks before baseline.\n* Able and willing to provide written informed consent and comply with study requirements, including scheduled visits and follow-up assessments.\n\nExclusion Criteria:\n\n* Presence of other autoimmune diseases.\n* Presence of severe, uncontrolled clinically significant organ dysfunction or other medical conditions that, in the investigator's judgment, would place the participant at unacceptable risk.\n* History of malignancy within 5 years prior to screening.\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study period.\n* Known hypersensitivity to tocilizumab, telitacicept, methotrexate, or any of their excipients.\n* Active hepatitis B or C virus infection, active tuberculosis, active herpes zoster infection, or a history of serious infection within 12 weeks prior to study treatment initiation (defined as an infection requiring hospitalization or intravenous antimicrobial therapy).\n* Severe hypoalbuminemia or serum immunoglobulin G (IgG) level \\\u003C6 g\u002FL.\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × the upper limit of normal (ULN), total bilirubin \\>1.5 × ULN, or creatinine clearance (CrCl) \\\u003C60 mL\u002Fmin.\n* Participation in another interventional clinical trial within 4 weeks prior to screening.\n* Inability to adequately perform pulmonary function testing or other study-related assessments.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.","ALL","18 Years","80 Years",{"count":20,"type":21},204,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.",[27],"Rheumatoid Arthritis Associated Interstitial Lung Disease",[29,30,31],"randomized controlled trial","Telitacicept","Tocilizumab","NOT_YET_RECRUITING","2026-06-07",{"date":35,"type":36},"2026-06-11","ACTUAL",{"date":38,"type":21},"2026-07-01",{"date":40,"type":21},"2029-07-31",{"name":42,"class":43},"Chinese SLE Treatment And Research Group","OTHER",22,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100630174","clinical-cohort-construction-and-therapeutic-effect-evaluation-of-integrated-traditional-chinese-and-western-medicine-in-the-treatment-of-rheumatoid-arthritis-100630174","NCT07484243","Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis","Inclusion Criteria:\n\n1. Meet the RA classification criteria established by ACR in 1987 or the revised RA diagnostic criteria by ACR\u002FEULAR in 2010;\n2. D2T-RA must comply with the D2T-RA diagnostic criteria by ACR\u002FEULAR in 2020 or the China D2T-RA diagnostic criteria in 2021;\n3. RA-ILD patients require joint evaluation by rheumatologists and pulmonologists, with a clear diagnosis of ILD and exclusion of other possibilities such as pneumoconiosis, allergic alveolitis, idiopathic pulmonary fibrosis, and other connective tissue disease-related interstitial lung diseases (CTD-ILD);\n4. Traditional Chinese medicine syndrome differentiation standards refer to the \"Guidelines for Diagnosis and Treatment of Rheumatoid Arthritis\" by the China Association of Chinese Medicine, the \"Clinical Research Guidelines for New Traditional Chinese Medicine Drugs\" by the National Medical Products Administration, and the \"Diagnostic and Therapeutic Criteria for Traditional Chinese Medicine Diseases\" by the Institute of Clinical Research of the China Academy of Chinese Medical Sciences;\n5. Receive traditional Chinese medicine treatment;\n6. Age ≥18 years;\n7. Sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe, progressive, or uncontrolled diseases of the kidneys, liver, blood, gastrointestinal tract, endocrine system, lungs, heart, nervous system, mental health, or brain, or current known malignant tumors;\n2. Known clinically significant environmental exposures that may cause pulmonary fibrosis (PF), including but not limited to dust, asbestos, beryllium, radiation, amiodarone, bleomycin, etc.;\n3. Poorly controlled severe asthma or chronic obstructive pulmonary disease (COPD) with medication adjustments within 3 months prior to screening;\n4. Active infections that the investigator deems may interfere with study assessment;\n5. Any clinically or laboratory abnormalities deemed significant by the investigator or other reasons that disqualify participants from this clinical study.",{"count":52,"type":21},10000,"OBSERVATIONAL","This is a large-scale, multicenter observational study on the treatment of rheumatoid arthritis (RA) with integrated Traditional Chinese and Western medicine.\n\nThe study plans to enroll at least 10,000 patients, including a minimum of 1,000 cases with difficult-to-treat RA (D2T RA) and 1,000 cases with RA-associated interstitial lung disease (RA-ILD). Through long-term follow-up, data will be collected on Traditional Chinese Medicine (TCM) syndrome characteristics, treatment plans, adverse drug reactions, and complications. Biological samples, including blood and urine, will also be collected.\n\nThe research will utilize multi-omics technologies such as genomics and proteomics, combined with clinical data, to deeply explore the modern scientific connotation of the \"disease-syndrome-symptom\" framework in RA. The goal is to clarify the patterns and advantages of TCM syndrome differentiation and treatment. Based on these findings, a scientific and standardized efficacy evaluation system for integrated treatment will be established, and optimized treatment strategies for D2T RA and RA-ILD will be developed.\n\nThe project is led by multiple national TCM clinical research centers and regional diagnostic and treatment centers, including the First Teaching Hospital of Tianjin University of TCM and Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine. These institutions have mature clinical research platforms, biobanks, and databases, providing a solid foundation for the successful implementation of this study.\n\nThe results of this research will provide a scientific basis for the integrated treatment of RA, promote the standardization of diagnostic and treatment protocols, and ultimately improve the overall level of RA prevention and treatment in China.",[56,57,58],"Rheumatoid Arthritis (RA)","Rheumatoid Arthritis-Associated Interstitial Lung Disease","Difficult-to-Treat Rheumatoid Arthritis","RECRUITING","2026-03-16",{"date":62,"type":36},"2026-03-20",{"date":64,"type":36},"2025-08-22",{"date":66,"type":21},"2029-03-31",{"name":68,"class":43},"Yuanyuan Zhang",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":69},"100192097","collection-of-airway-blood-andor-urine-specimens-from-subjects-for-research-studies-100192097","NCT01776398","Collection of Airway, Blood and\u002For Urine Specimens From Subjects for Research Studies","Inclusion Criteria:\n\nGroup 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS (Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.):\n\n* All study subjects should be able to provide informed consent\n* Males or females ages 18 years and older\n* Must provide HIV informed consent\n\nGroup 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE (As defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.):\n\n* Must provide informed consent\n* Males and females age 18 years and older\n* Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and\u002For (6) diseases of organs with known association with lung disease\n* Must provide HIV informed consent\n\nAdditional Inclusion criteria for CF subjects:\n\n• All CF subjects will be homozygous for the ΔF508 mutation, with mild-moderate lung disease as defined by FEV1 ≥ 50%\n\nGroup 2 - WCMC\u002FNYPH CLINICAL PATIENTS\n\n* Must provide informed consent\n* Males and females, age 18 years and older\n* Lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) diseases of organs with known association with lung disease, and (7) individuals with the blood eosinophil levels of 5% or greater.\n\nGroup 3 - PCNY CLINICAL PATIENTS VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE\n\n* Must provide informed consent\n* Males and females, age 18 years and older\n* Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease\n\nExclusion Criteria:\n\nGroup 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS\n\n* Individuals not deemed in good overall health by the investigator during screening visits and\u002For prior to the bronchoscopy will not be accepted into the study.\n* Individuals with history of chronic lung disease, including asthma or with recurrent or recent (within three months) acute pulmonary disease will not be accepted into the study.\n* Individuals with allergies to atropine or any local anesthetic will not be accepted into the study.\n* Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or aminophylline will not be accepted into the study.\n* Females who are pregnant or nursing will not be accepted into the study\n\nGroup 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE\n\n* Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic will not be included in the study\n* Individuals deemed unable to complete the bronchoscopy due to health concerns by the investigator.\n* Females who are pregnant or nursing\n\nAdditional Exclusion criteria for CF subjects:\n\n* Experienced a recent (≤ 8 weeks) pulmonary exacerbation of their disease\n\nGroup 2 - WCMC\u002FNYPH CLINICAL PATIENTS\n\n* Patient refuses consent\n\nGroup 3 - PCNY CLINICAL PATIENTS\n\n* Patient refuses consent",true,{"count":78,"type":21},2000,"The purpose of this study is to obtain biologic materials from the blood, airways and\u002For urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters. These provide control information when compared to individuals with various pulmonary diseases, and will help in understanding of the etiology and pathogenesis of various lung diseases. The underlying hypothesis is that the pathologic morphological changes in the airway epithelium must be preceded by changes in the gene expression pattern of the airway epithelium and potentially in macrophages.",[81,82,83,84,57,85],"Chronic Obstructive Pulmonary Disease (COPD)","Smoking","Smoking Cessation","Idiopathic Pulmonary Fibrosis (IPF)","Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)",[87,88,89,90,82,91,92,93,94,95,96,97,57,98],"COPD","Chronic Obstructive Pulmonary Disease","Lung disease","Emphysema","Healthy Smoker","Smoker","Non-smoker","IPF","RA-ILD","SSC-ILD","Idiopathic Pulmonary Fibrosis","Scleroderma-Associated Interstitial Lung Disease","2025-11-12",{"date":101,"type":36},"2025-11-14",{"date":103,"type":36},"2012-08-29",{"date":105,"type":21},"2028-12",{"name":107,"class":43},"Weill Medical College of Cornell University"]